Log in to search using one of your social media accounts:

 

EPTIFIBATIDE Injection, Solution [Akorn, Inc.]
Updated Date: May 2, 2017 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - May 2, 2017 Category: Drugs & Pharmacology Source Type: news

Integrilin (etifibatide) Injection (Etifibatide Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 17, 2017 Category: Drugs & Pharmacology Source Type: news

EPTIFIBATIDE Injection [Amneal Biosciences]
Updated Date: Dec 14, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - December 14, 2016 Category: Drugs & Pharmacology Source Type: news

EPTIFIBATIDE Injection, Solution [Teva Parenteral Medicines, Inc.]
Updated Date: Jul 6, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - July 6, 2016 Category: Drugs & Pharmacology Source Type: news

Studying for USMLE Step 2? Master this most missed question
Studying for the United States Medical Licensing Examination® (USMLE®) Step 2 may seem daunting, but not to fear. Starting this month, we’re giving you an exclusive scoop on the most missed USMLE Step 2 test prep questions and expert strategies to help you beat them. Check out this month’s most challenging question, and view an expert video explanation of the answer from Kaplan Medical. Welcome to the first Step 2 post in AMA Wire’s® series, “Tutor talk: Tips from Kaplan Medical on the most missed USMLE test prep questions from Kaplan’s Qbank.” Each month, we’re ...
Source: AMA Wire - February 24, 2016 Category: Journals (General) Authors: Amy Farouk Source Type: news

EPTIFIBATIDE Injection [Aurobindo Pharma Limited]
Updated Date: Dec 10, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - December 10, 2015 Category: Drugs & Pharmacology Source Type: news

EPTIFIBATIDE Injection [AuroMedics Pharma LLC]
Updated Date: Dec 10, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - December 10, 2015 Category: Drugs & Pharmacology Source Type: news

Aurobindo gets USFDA nod to market heart disease drug
Aurobindo Pharma has received US health regulator's approval to market Eptifibatide Injection, used in the treatment of acute coronary syndrome, in the American market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 9, 2015 Category: Pharmaceuticals Source Type: news

EPTIFIBATIDE Injection, Solution [Teva Parenteral Medicines, Inc.]
Updated Date: Aug 13, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 13, 2015 Category: Drugs & Pharmacology Source Type: news

INTEGRILIN (Eptifibatide) Injection, Solution [Merck Sharp Dohme Corp.]
Updated Date: Mar 5, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 5, 2015 Category: Drugs & Pharmacology Source Type: news

INTEGRILIN (Eptifibatide) Injection, Solution [Merck Sharp Dohme Corp.]
Updated Date: Aug 27, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 27, 2014 Category: Drugs & Pharmacology Source Type: news

Anticoagulant otamixaban does not reduce rate of ischemic events among certain patients undergoing PCI
Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non-ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 3, 2013 Category: Consumer Health News Tags: Surgery Source Type: news

TAO: Otamixaban Disappoints in NSTE-ACS TAO: Otamixaban Disappoints in NSTE-ACS
The new IV factor Xa inhibitor was not superior to heparin plus eptifibatide in reducing death/MI but did increase bleeding among patients with NSTE-ACS and a planned invasive strategy. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 1, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

TAO: Otamixaban disappoints in NSTE-ACS
The new IV factor Xa inhibitor was not superior to heparin plus eptifibatide in reducing death/MI but did increase bleeding among patients with NSTE-ACS and a planned invasive strategy. (Source: theHeart.org)
Source: theHeart.org - September 1, 2013 Category: Cardiology Source Type: news

ESC: Otamixaban Fails in ACS (CME/CE)
AMSTERDAM (MedPage Today) -- The novel drug otamixaban failed to make a difference in preventing ischemic events among patients with non-ST-segment elevation myocardial infarction when compared with heparin and eptifibatide (Integrilin), a study found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 1, 2013 Category: Cardiology Source Type: news

Anticoagulant does not reduce rate of ischemic events among certain patients undergoing PCI
(The JAMA Network Journals) Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non-ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 1, 2013 Category: Global & Universal Source Type: news

Bivalirudin linked to less bleeding, but more severe complications, vs. eptifibatide
Read the full story on MD Consult: Bivalirudin linked to less bleeding, but more severe complications, vs. eptifibatide (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - August 23, 2013 Category: Journals (General) Source Type: news

Study shows combination stroke therapy safe and effective
The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati (UC) researchers has found. Results from the study, known as the CLEAR-ER Stroke Trial, are published online in the journal Stroke: Journal of the American Heart Association. UC was the coordinating center for the trial, which included nine medical centers comprising 21 hospitals... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 1, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Study shows combination stroke therapy safe and effective
(University of Cincinnati Academic Health Center) The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati researchers has found. Results from the phase-2 clinical trial, known as the CLEAR-ER Stroke Trial, are published online in the journal Stroke: Journal of the American Heart Association. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 30, 2013 Category: Global & Universal Source Type: news

Adjunctive Use of Eptifibatide for Complication Management During Elective Neuroendovascular ProceduresAdjunctive Use of Eptifibatide for Complication Management During Elective Neuroendovascular Procedures
Is the antiplatelet agent eptifibatide an effective therapeutic strategy in the event of thromboembolism during elective neuroendovascular procedures? Journal of Neurointerventional Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 15, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

INTEGRILIN (Eptifibatide) Injection, Solution [Merck Sharp Dohme Corp.]
Updated Date: Apr 11, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - April 11, 2013 Category: Drugs & Pharmacology Source Type: news

Eptifibatide plus tPA looks promising for ischemic stroke
A phase 2 study has suggested that the GP IIb/IIIa blocker can be safely combined with a reduced dose of tPA, and there was a sufficient signal of efficacy to justify a phase 3 trial. (Source: theHeart.org)
Source: theHeart.org - February 15, 2013 Category: Cardiology Source Type: news

Eptifibatide Plus tPA Looks Promising for Ischemic StrokeEptifibatide Plus tPA Looks Promising for Ischemic Stroke
A phase 2 study has suggested that the glycoprotein IIb/IIIa blocker can be safely combined with a reduced dose of tPA, and there was a sufficient signal of efficacy to justify a phase 3 trial. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 14, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news